NewAmsterdam Pharma doses first patient in Phase 2b SPINOZA Alzheimer's trial
NewAmsterdam Pharma announced that it dosed the first participant in SPINOZA, a Phase 2b trial evaluating obicetrapib in about 400 people with preclinical Alzheimer's disease. The trial will randomize participants 1:1 to obicetrapib 10 mg or placebo for 52 weeks, with the primary endpoint being change in plasma p-tau217 at Week 52. The filing contains no financial results, so the news is a clinical development milestone rather than a change in the company's reported performance.
Key points
- First participant dosed in SPINOZA, announced September 29, 2026
- Trial plans about 400 participants, randomized 1:1 to obicetrapib 10 mg or placebo for 52 weeks
- Primary endpoint is change from baseline to Week 52 in plasma p-tau217
- Builds on BROADWAY Alzheimer's biomarker analysis, which showed statistically significant lower p-tau217 changes versus placebo over 12 months (p=0.025 in the full analysis set)
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.